Search results
Results From The WOW.Com Content Network
Covaxin (development name, BBV152) is a whole inactivated virus-based COVID-19 vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research - National Institute of Virology.
It was founded 13 November 1924 in India under the name of H.J.Foster & Co. Limited as an Agency House for distributing Baby Food Glaxo, Joseph Nathan & Co. In 1950, it changed its name to Laboratories (I) Ltd. [1] Old GlaxoSmithKline logo until 9 June 2022
ZyCoV-D is a DNA plasmid-based COVID-19 vaccine developed by Indian pharmaceutical company Cadila Healthcare, with support from the Biotechnology Industry Research Assistance Council. It is approved for emergency use in India.
The Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, [37] is an mRNA vaccine [156] produced by the German company BioNTech and the American company Pfizer. [ 156 ] [ 157 ] [ 158 ] In Hong Kong, Macau, and Taiwan, Comirnaty is distributed by Fosun Pharma .
The company started its operations in Pakistan as Glaxo Laboratories Pakistan Ltd and was listed on the Karachi Stock Exchange in 1951. [3]GSK Pakistan equation was formed when Beecham, Glaxo Welcome and Smith Kline, all having a big name in the pharmaceutical market and that were separate entities before, merged in 2002.
Serum Institute of India partnered with the British-Swedish multinational pharmaceutical company AstraZeneca for developing AZD1222 (Covishield) in partnership with the University of Oxford. [19] It was reported that Serum Institute of India would provide 100 million (10 crore) doses of the vaccine for India and other low and middle-income ...
Bhutan and Maldives were the first countries to receive vaccines as a grant by India. This was quickly followed by shipments to Nepal, Bangladesh, Myanmar and Seychelles. [176] By mid-March 2021, India was also supplying vaccines on a commercial basis to countries including Canada, [177] the UK, [178] and Saudi Arabia. [179]
A high-dose vaccine (Fluzone High-Dose) four times the strength of standard flu vaccine was approved by the FDA in 2009. [22] [23] [24] This vaccine is intended for people 65 and over, who typically have weakened immune response due to normal aging. The vaccine produces a greater immune response than standard vaccine.